Alliancebernstein L.P. Sells 654 Shares of Natus Medical Incorporated (NASDAQ:NTUS)

Alliancebernstein L.P. lowered its position in Natus Medical Incorporated (NASDAQ:NTUS) by 1.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 57,256 shares of the company’s stock after selling 654 shares during the period. Alliancebernstein L.P.’s holdings in Natus Medical were worth $1,324,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in NTUS. Janus Henderson Group PLC bought a new position in Natus Medical in the fourth quarter worth approximately $58,950,000. Cramer Rosenthal Mcglynn LLC bought a new position in shares of Natus Medical in the fourth quarter valued at approximately $45,658,000. State Street Corp bought a new position in shares of Natus Medical in the fourth quarter valued at approximately $39,079,000. Nuveen Asset Management LLC bought a new position in shares of Natus Medical in the fourth quarter valued at approximately $35,368,000. Finally, Victory Capital Management Inc. bought a new position in shares of Natus Medical in the fourth quarter valued at approximately $34,251,000. Institutional investors and hedge funds own 89.21% of the company’s stock.

Shares of NTUS opened at $21.45 on Wednesday. The company has a current ratio of 2.13, a quick ratio of 1.60 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $694.64 million, a price-to-earnings ratio of 59.58 and a beta of 0.85. The stock has a 50 day moving average of $21.82 and a 200 day moving average of $26.70. Natus Medical Incorporated has a 12 month low of $18.91 and a 12 month high of $34.89.

Natus Medical (NASDAQ:NTUS) last issued its quarterly earnings results on Thursday, April 30th. The company reported $0.04 EPS for the quarter, missing the Zacks’ consensus estimate of $0.22 by ($0.18). The business had revenue of $109.40 million for the quarter, compared to analysts’ expectations of $115.00 million. Natus Medical had a net margin of 2.51% and a return on equity of 9.91%. The firm’s revenue for the quarter was down 4.9% compared to the same quarter last year. As a group, equities research analysts predict that Natus Medical Incorporated will post 0.5 earnings per share for the current year.

NTUS has been the topic of a number of recent research reports. TheStreet lowered Natus Medical from a “c-” rating to a “d+” rating in a report on Friday, March 27th. Zacks Investment Research lowered Natus Medical from a “hold” rating to a “sell” rating in a report on Tuesday, June 16th. Finally, BidaskClub lowered Natus Medical from a “sell” rating to a “strong sell” rating in a report on Friday, June 19th.

Natus Medical Profile

Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

Featured Article: What are no-load funds?

Want to see what other hedge funds are holding NTUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natus Medical Incorporated (NASDAQ:NTUS).

Institutional Ownership by Quarter for Natus Medical (NASDAQ:NTUS)

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.